Erlotinib Terminated Phase 2 Trials for Head and Neck Carcinoma Treatment

IndicationsStatusPurposePhase
TerminatedTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT00750555Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer